Objectives: Oral cancer is the sixth most common malignancy worldwide. Cancer development and progression requires inactivation of tumour suppressor genes and activation of proto-oncogenes. Expression of these genes is in part dependant on RNA and microRNA based mechanisms. MicroRNAs are essential regulators of diverse cellular processes including proliferation, differentiation, apoptosis, survival, motility, invasion and morphogenesis. Several microRNAs have been found to be aberrantly expressed in various cancers including oral cancer. The purpose of this article was to review the literature related to microRNA deregulation in the head and neck/oral cavity cancers. Material and Methods: A comprehensive review of the available literature from 2000 to 2011 relevant to microRNA deregulation in oral cancer was undertaken using PubMed, Medline, Scholar Google and Scopus. Keywords for the search were: microRNA and oral cancer, microRNA and squamous cell carcinoma, microRNA deregulation. Only full length articles in the English language were included. Strengths and limitations of each study are presented in this review. Results: Several studies were identified that investigated microRNA alternations in the head and neck/oral cavity cancers. Significant progress has been made in identification of microRNA deregulation in these cancers. It has been evident that several microRNAs were found to be deregulated specifically in oral cavity cancers. Among these, several microRNAs have been functionally validated and their potential target genes have been identified. Conclusions: These findings on microRNA deregulation in cancer further enhance our understanding of the disease progression, response to treatment and may assist with future development of targeted therapy.
INTRODUCTION
Cancer of the oral cavity and oropharynx (OCC) remains among the top ten malignancies in the United States and worldwide. These cancers account for 4% of malignancies in men and 2% of malignancies in women. In the United States despite current advances in treatment one human life every hour is lost to this cancer. According to American Cancer Society while overall new head and neck/oral cavity cancer cases increased about 8% during the past 5 years, the new cases for oral cancer increased about 21% (Table 1 ). In the 2010 cancer statistics published by the American Cancer Society there are 36,540 estimated new cases of oral cavity/oropharynx cancers and 7,880 deaths from these cancers [1] . An alarming fact is the recent increase of these cancers worldwide among younger individuals often without risk factors or not engaged in known high risk social habits such as smoking and alcohol consumption [2, 3] . Despite current advances in treatment the reported overall five year disease free survival worldwide remains largely unchanged over the past several decades for all races (range between 45 -65%) [1, [4] [5] [6] [7] . Failure to cure OCC despite optimal treatment is a reality and these cancers remain an undertreated and poorly understood disease process that represents a major health problem. Improvement of survival and treatment outcomes require a better understanding of the disease progression so that these cancers can be diagnosed early and most importantly targeted therapy can be initiated accordingly. The initiation and progression of OCC is a highly complex multistep process that entails progressive acquisition of genetic and epigenetic alterations and dynamic changes in the genome. Thus far, the majority of the studies on the cancer genome have focused primarily on the protein coding genes and their alterations. The impact of non coding sequences in disease initiation and progression including cancers remain largely unknown [8] [9] [10] . Although at least 65% of the genome is transcribed, protein-coding transcripts are derived from less than 2% of the human genome [11] . The mammalian genome harbours genes that although they do not encode proteins have an important role in normal cell development and disease process and these non protein transcripts may make up at least half of all transcripts in mammals [12] . RNA interference (RNAi) in a variety of organisms is a known process of sequence specific post-transcriptional gene silencing initiated by double-stranded RNA [13, 14] . RNAi was first discovered in 1998 in the neomatome Ceanorhabditis elegans, but is conserved in variety of organisms and is considered a major regulatory mechanism in eukaryotic gene expression [15] . In mammalian cells RNAi regulation of endogenous genes occurs by the production of short double-stranded RNA molecules or microRNA. MicroRNAs mediate gene expression at the post-transcriptional level by degrading or repressing target messenger RNAs (mRNA) or by translational inhibition of target genes. Since the initial discovery of the founding members of the microRNA family, lin-4 and let-7 several hundreds have been identified in all species by combination of molecular cloning and bioinformatics. It is now estimated that 1,000 microRNAs exist in the human genome [16] [17] [18] [19] [20] [21] [22] [23] [24] . The purpose of this article was to review the literature related to microRNA deregulation in the head and neck/ oral cavity cancers.
MATERIAL AND METHODS
A comprehensive review of the available literature from 2000 to 2011 relevant to microRNA deregulation in oral cancer was undertaken using PubMed, Medline, Scholar Google and Scopus. Keywords for the search were: microRNA and oral cancer, microRNA and squamous cell carcinoma, microRNA deregulation. Only full length articles in the English language were included. Strengths and limitations of each study are presented in this review.
MicroRNA formation
MicroRNAs are encoded by genes located either in non coding regions or in introns of protein coding genes and require a complex set of proteins for their formation [25, 26] . Thus primary microRNA transcription may be by an independent promoter or by a promoter of the proximal coding gene. G) and poly-adenylated at the 3' end. This is a process similar to protein-coding messenger RNA process. The primary microRNAs form specific hairpin-shaped stem loop secondary structures prior to be processed by a microprocessor complex (500 -650 kDa) into pre-microRNAs. The complex, consistent of Drosha (RNase III endonuclease) and the essential cofactor DGCR8/Pasha, processes the primary mircoRNAs into 60-to 70-nucleotide long pre-microRNA with a 5' phosphate and a 3' nucleotide overhang. Exportin 5, a member of the Ran transport receptor family, transports the pre-microRNA to the cytoplasm. In the cytoplasm further processing to short double strand microRNA/microRNA* occurs by Dicer, a second RNase III endonuclease, prior to unwind of the duplex by a helicase to reveal the final mature microRNA and microRNA*, which is quickly degraded [27] . The average ratio of microRNA to microRNA* is approximately 100 to 1 but can be much lower in cases of both strands are functional and incorporated into RISC that is shown to occur [27] [28] [29] . The mature microRNA product is noncoding, regulatory RNA molecules 22 nucleotides long that can be asymmetrically incorporated into RNA-induced silencing complexes (RISC) that are then guided to the target mRNA [9, [30] [31] [32] .
MicroRNA physiologic functions
It is well established that microRNAs are involved in diverse physiologic processes [33] [34] [35] [36] . Studies with mouse embryos and zebra fish Dicer-null phenotype revealed that microRNA pathway is not generally required for cellular viability but plays a prominent role in various tissue specific cell types and morphogenesis of embryonic structures. Such examples are impact of microRNAs on T-cell development/differentiation as well as morphogenesis of lung, limp and skin as well as maintenance of hair follicles [37] [38] [39] [40] [41] [42] . The ability of microRNAs to dramatically influence tissue(s) specific generation and behaviour is another important function of these molecules. This is demonstrated in studies on microRNA-181, the first mammalian microRNA to be carefully studied as well as microRNA-1 the most highly conserved microRNA. MicroRNA-181's ectopic expression in hematopoietic progenitor cells skews their differentiation towards the B-cell lineage while the same microRNA is up-regulated during differentiation and regeneration of muscle cells [43, 44] . MicroRNA-1 conversely demonstrates skeletal and cardiac muscle specific expression and is shown to be critical in development of normal muscle [21, 45, 46] . Over-expression or inhibition of microRNA-1 promotes or inhibits respectively mammalian muscle cell differentiation in vitro [45, 47] . In addition microRNA-1 has been shown to also play an important role in muscle physiology [45, [48] [49] [50] . The involvement of microRNA-138, that is also frequently deregulated in OSCC as will be discussed later, in differentiation of human adipose tissue derived mesenchymal stem cells is another recent discovery. During adipose differentiation microRNA-138 was found to be significantly downregulated, while it's over expression effectively reduced lipid droplets accumulation and inhibit expression of key adipogenic transcription factors. These findings could provide insights into the pathogenesis of a number of diseases such as obesity and diabetes and potentially broaden the spectrum of stem cell based therapy for these conditions [51] . These findings stress the fact that a single microRNA can participate and impact on distinct pathways in various tissues and have the ability to influence the generation and behaviour of tissuespecific cell types. It is now accepted that microRNAs are important in establishing and/or maintaining gene expression patterns that are characteristic of specific tissues [52] . It has been shown that many microRNAs and their predicted target are reciprocally expressed [53, 54] . Lastly, several cell-autonomous functions, not related to development or differentiation, have been shown to be controlled by microRNAs. Such examples include insulin regulation and specific expression of microRNA-375 in pancreatic islet beta cells and cholesterol homeostasis by liver specific microRNA-122. The brain and nervous system is perhaps the most extensively studied in reference to microRNA and regulation of function in vertebras. For example neuronal differentiation and synaptic function have been found to be controlled by microRNA-9 and microRNA-124 while neuronal outgrowth and dendritic morphogenesis by microRNA-134, microRNA-132. Another interesting implication of microRNAs in function has originated from identification of microRNA-138 involvement in dendritic spine size morphogenesis, via synaptic protein synthesis, that is associated with formation of long lasting memories [55] [56] [57] [58] [59] [60] [61] . In addition to key roles in the nervous system development and function micrRNA-138 has been implicated in cardiac patterning-compartmentalization during embryonic development [62] . It is evident from the current and growing literature that microRNAs have global participation and impact on normal physiologic processes. A logical extension to this conclusion is that any alteration or abnormalities in
their function would influence disease phenotypes in all organisms [44, 63, 64] . Additional information on microRNA functions and microRNAs in physiology and disease process can be found in the excellent reviews on the subject by Bushati et al. and Chang et al. [63, 64] .
MicroRNA and cancer of the oral cavity and oropharynx (OCC)
Since their initial discovery the microRNA gene family is continuously growing with novel members discovered in association with several disease processing. [70, 71] . Laser dissected cells from four tongue cancers and paired normal tissue were used to examine expression levels of 156 human mature microRNAs using qRT-PCR (Tan Man microRNA Assays; Human Panel). Twenty four microRNAs, including microRNA-184 and microRNA-21, were up-regulated and 13 were down-regulated, including microRNA-100, microRNA -125, microRNA-133a and microRNA-133b. A 3-fold expression difference was the cut-off level used [70, 71] . In their attempt to identify a microRNA signature specific to oral cavity squamous cell carcinoma, Kozaki et al. in 2008 examined the expression profile of 148 microRNAs in 18 cancer cell lines and immortalized oral keratinocyte line RT7 that served as control [72] . The cancer cell lines originated from ten stage 2 (T2) and one stage 4 (T4) frozen primary samples. The expression levels of the microRNA genes were examined using the Tan Man microRNA assay (Applied Biosystems). Eleven micro-RNAs were up-regulated by at least 1.5-fold expression or higher and 54 were downregulated by less than 0. (1 out of 5) were compared to normal tissue harvested from adjacent to the tumour [74] . In addition to identifying 16 up-regulated microRNAs (including microRNA-21) and 4 down-regulated microRNAs the study demonstrated potential for stratification of tumour versus adjacent normal tissue based on the differential expression of microRNA and their targeted genes. A comprehensive list of the studies demonstrating microRNA deregulation in head and neck/oral cancer is provided in Table 2 .
Most recently, Clague et al. in 2009 examined the potential role of microRNA polymorphism in identifying patients with oral premalignant lesions (OPL) that maybe at high risk for progression into cancer [75] . They concluded that individual and combined genotypes of microRNA-related variants could potentially be used to predict risk for progression. The potential role of microRNAs in tumour progression was investigated by Scapoli et al. using microarray analysis the group examined 15 oral cancers (8 without evidence of metastasis and 7 with nodal involvement) and among the 19 deregulated microRNAs they identified three (let-7i, microRNA-155 and microRNA146a) to be associated with disease progression, signified by nodal involvement [76] . Lajer et al. in 2011 identified differences in microRNA expression patterns of normal epithelia and squamous cell carcinoma of the oral cavity and developed a molecular classifier that included 61 microRNAs and provided 93% accuracy [77] . In addition the group concluded that HPV (human papilloma virus) infected tumours may have a distinct clinical behaviour potentially due to influence of HPV on microRNA.
MicroRNA deregulation in oral cancer and prognosis
In addition to exploring microRNA deregulation some studies have attempted to demonstrate an association between microRNA expression in head and neck including oral cavity cancer and survival. [78] . Another interesting population-based case-control study that included 513 cancers (283 oral cancer, 132 pharyngeal and 98 laryngeal cancers) and 597 controls (matched to cases by gender, age and town of residency) examined the let-7 microRNA-binding site polymorphism in the KRAS 3' UTR that arises in the let-7 complementary site. This leads to a KRAS-LCS6 variant allele that alters the expression of KRAS and levels of let-7. The interest in this phenomenon was driven by observations that when this variant allele was identified in lung cancers it was associated with poor outcome [79] . The let-7 microRNA family regulates KRAS functioning as tumour suppressor gene. Lung, pancreas and colon adenocarcinomas activation of KRAs proto-oncogene via mutation is a well documented phenomenon [80] . Although KRAS mutations are rare in cancers of the head and neck, amplifications of KRAS have been reported in squamous cell carcinomas originating from this site [81, 82] . In this study two important observations were made: KRAS-LCS6 variant allele was significantly associated with poor prognosis and the prognosis was worse in cancers originating in the oral cavity [79] . Metastasis is the major distinctive event in malignancy progression and severely impacts on prognosis. Using three pairs of cancer cell lines from the head and neck with differences in migration and invasion identified several microRNAs to be deregulated many of them previously implicated in tumorigenesis and metastasis [83] . These included let-7 family members, microRNA-7, microRNA-16, microRNA-21, microRNA-27 family, microRNA microRNA106b, , and microRNA-224 [69, [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] . Among the identified microRNA deregulations, reduced expression of microRNA-138 was consistently observed in the highly invasive cell lines [103] . Downregulation of microRNA-138 has been previously observed in SCC of the tongue, thyroid carcinoma, lung cancer in never smokers and has been implicated in multidrug resistance of leukaemia cells [71, 99, 103, 104] .
DISCUSSION
The majority of these studies especially early on utilized [105] .
CONCLUSIONS
Significant progress has been made in identification of specific microRNAs that are consistently deregulated in oral cavity cancers. From the available studies, it can be concluded that microRNA-21 and let-7 are among the microRNAs found to be always up-regulated in cancers of the oral cavity and oropharynx versus controls while microRNA-133a and microRNA-133b are consistently down-regulated. Among the deregulated microRNAs, several have been functionally validated and their potential target genes have been identified (Table 3) . Several other microRNAs known to be involved in carcinogenesis are reported with some conflicting findings potentially due to the study limitations mentioned earlier. Additional evidence exists on specific roles of these molecules and their involvement in pathways, known to be altered in cancer of the oral cavity and oropharynx as shown in table 3.
The expanding knowledge of specific roles of certain microRNAs is further contributing to our understanding of the complexity of tumour progression and behaviour. Consideration of this information and incorporation into treatment modalities through targeted therapy could potentially enhance our abilities to improve outcome especially when other established therapies have failed.
ACKNOWLEDGMENTS AND DISCLOSURE STATEMENTS
The authors have no conflict of interest to declare. 
